Serum neurofilaments increase at progressive multifocal leukoencephalopathy onset in natalizumab‐treated multiple sclerosis patients. Issue 4 (5th March 2019)

• Record Type: Journal Article
• Authors: Dalla Costa, Gloria; Martinelli, Vittorio; Moiola, Lucia; Sangalli, Francesca; Colombo, Bruno; Finardi, Annamaria; Cinque, Paola; Kolb, Eva‐Maria; Haghikia, Aiden; Gold, Ralf; Furlan, Roberto; Comi, Giancarlo
• Is Part Of: Annals of neurology. Volume 85:Issue 4(2019)
• Page Start: 606
• Page End: 610
• Publication Date: 2019-03-05
• Subjects: Neurology -- Periodicals; Pediatric neurology -- Periodicals; Nervous system -- Surgery -- Periodicals; 616.8
• DOI: 10.1002/ana.25437
• Languages: English
• ISSNs: 0364-5134

Abstract

Abstract : This study analyzed serum neurofilament light chains (NfL) in 2 European cohorts of 312 multiple sclerosis (MS) patients to investigate whether NfL are biomarkers of progressive multifocal leukoencephalopathy (PML) during natalizumab treatment. The cohort comprised 25 PML, 136 natalizumab‐treated, and 151 untreated MS patients. Patients subsequently developing PML had similar NfL to other natalizumab‐treated MS patients. At PML onset, NfL were 10‐fold higher than in the pre‐PML condition and in natalizumab‐treated or untreated MS patients, and NfL continued to increase until onset of immune reconstitution inflammatory syndrome. The results suggest that in natalizumab‐treated patients, NfL may represent an early and accessible marker of PML. Ann Neurol 2019;85:606–610